AnaptysBio pro forma continuing ops net income $114.9M after First Tracks spin-off

ANAPTYSBIO, INC

Pro forma continuing ops net income $114.9M for FY2025; basic EPS $3.99, diluted $3.07.
Collaboration revenue $234.6M, operating income $217.9M after spin-off adjustments.
AnaptysBio provided $100M cash distribution to First Tracks; expects $7M non-recurring costs within 12 months.
Pro forma balance sheet as of Dec 31, 2025 shows negative stockholders' equity of $116.3M.
First Tracks shares began trading on Nasdaq under ticker TRAX on April 20, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.